Emerald Health Looks To Delist From The TSX Venture
Emerald Health Therapeutics (TSXV: EMH) this morning announced that it is looking to delist from the TSX Venture and in exchange list its equity on the Canadian Securities Exchange. The change in listing is expected to allow for “increased flexibility to conduct business.”
It appears that the company may be looking south of the border to the cannabis market based on the text provided, especially as it pertains to the ability to have increased flexibility in its operations. Commenting on the announcement, CEO Riaz Bandali stated, “we look forward to this proactive listing change to the CSE to allow us to more readily expand the geographic focus of our business beyond just Canada,” further insinuating such a move.
The company also cited lower filing, compliance, legal and other fees as justification for the move.
Once approved for listing on the CSE, the company will seek approval for delisting from the TSX Venture.
Emerald Health last traded at $0.315 on the TSX Venture.
Information for this briefing was found via Sedar and Emerald Health Therapeutics. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.
